In Germany, chemosensitivity tests are routinely conducted in order to determine which chemotherapy drugs should be utilized for a specific cancer patient.
Because some tumors may resist certain chemotherapy treatments, some oncologists are choosing to test tumor cells in advance of treatment rather than prescribe a standard chemotherapy combination without knowing whether it would be effective for your particular tumor.
The tests, called chemotherapy sensitivity and resistance assays (CSRAs) are relatively new and are carried out for many types of cancer.
The CSRA is a laboratory test that is done on a single cell in a test tube (in vitro) or on a clump of tumor cells (in vivo), usually taken from a biopsy tissue sample. The test assesses how many cancer cells are killed by a particular drug, or by a combination of drugs, and how many cancer cells are unaffected by the treatment.
When your oncologist examines these test results, he/she can then treat you more effectively, knowing which chemo drugs your cells respond to. Two more added benefits are that you don’t lose any time being blasted with drugs that don’t work for you and you don’t have to be debilitated by the side effects of drugs that won’t kill your cancer.
There Are 5 Qualifying Factors
As of writing this article, I am aware of 5 qualifying factors before you will be considered for a chemosensitivity test.
Insurance Companies and Clinical Trial Results – Two More Problems
Not all insurance companies will cover the cost of the chemosensitivity test, which as close as I could tell runs around $800. Aetna Insurance considers chemosensitivity assays “experimental and investigational because there is insufficient evidence that these assays influence management decisions such that clinical outcomes are improved.” I guess Germany doesn’t count.
It appears that independent clinical trials are still underway here in America and because of that this test is not standard, and it will not be offered to every patient until doctors are convinced of its accuracy and value.
It’s Just My Opinion, But…
If the chemosensitivity test assists oncologists to tailor make a chemo regimen that is going to be the most effective for our specific cancer, why wouldn’t the insurance companies pay for this? It could conceivably lead to less chemo treatments and a patient who is actually ALIVE at the end of the treatment regimen (as opposed to one who won’t be paying any more insurance premiums due to being 6 feet under!).
I think that if toxic chemotherapy is going to continue to be the standard of care (which many consider outdated and prehistoric) they need to step up the clinical trials and get these results back as quickly as they can so that ALL can be given these tests and ensure they have the best response rate to the chemotherapy drugs and the greatest chance at beating cancer.
Finally, take 7 minutes out of your busy day and watch this interesting You Tube video – Burton Goldberg interviews Professor Michael Geising, a German Molecular Oncologist from Munster, Germany. Dr Geising advises “only 15-20% of chemotherapies are successful. The other 80% not only don’t work, but 60% of them actually make the cancer more aggressive by allowing it to develop resistance mechanisms.”
Research strongly suggests that when patients receive the most effective treatment, matched to their cancer profile, they survive longer. Ask your oncologist about the chemosensitivity test. In fact, insist on it.
If you’d like to stay connected, sign up for my free e-newsletters on the right, or “like” me on Facebook (MarnieClark.com) and I’ll do my utmost to keep you informed and empowered on your healing journey… and beyond.